PE20030323A1 - Composicion farmaceutica - Google Patents
Composicion farmaceuticaInfo
- Publication number
- PE20030323A1 PE20030323A1 PE2002000832A PE2002000832A PE20030323A1 PE 20030323 A1 PE20030323 A1 PE 20030323A1 PE 2002000832 A PE2002000832 A PE 2002000832A PE 2002000832 A PE2002000832 A PE 2002000832A PE 20030323 A1 PE20030323 A1 PE 20030323A1
- Authority
- PE
- Peru
- Prior art keywords
- tablet
- pharmaceutical composition
- fluoroanilyline
- cyclooxygenase
- polyvinylpyrrolidone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
PARA TRATAR UN TRANSTORNO O UNA CONDICION DEPENDIENTES DE CICLOOXIGENASA-2, CARACTERIZADA PORQUE COMPRENDE: A)UNA TABLETA DE LIBERACION INMEDIATA DE 400 mg DE ACIDO 5-METIL-2-(2´-CLORO-6´-FLUOROANILINO) FENILACETICO O UNA SAL DEL MISMO FARMACEUTICAMENTE ACEPTABLE COMO AGENTE ACTIVO QUE ESTA PRESENTE EN LA TABLETA ENTRE 60% Y 70%, EN PESO; Y, B)6,6% DE POLIVINILPIRROLIDONA; C)4,3% DE CROSCARAMELOSA SODICA; D)0,5% DE ESTEARATO DE MAGNESIO; Y, E)23,56% DE CELULOSA MICROCRISTALINA. DONDE, LA TABLETA NO COMPRENDE SUFICIENTES COMPONENTES INSOLUBLES EN AGUA O POLIMERICOS QUE IMPARTAN A LA COMPOSICION CARACTERISTICAS DE LIBERACION PROLONGADA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31638901P | 2001-08-31 | 2001-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030323A1 true PE20030323A1 (es) | 2003-05-12 |
Family
ID=23228840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000832A PE20030323A1 (es) | 2001-08-31 | 2002-08-29 | Composicion farmaceutica |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20030114527A1 (es) |
| EP (1) | EP1425005B1 (es) |
| JP (1) | JP4636796B2 (es) |
| KR (1) | KR100895551B1 (es) |
| CN (1) | CN100406008C (es) |
| AR (1) | AR036312A1 (es) |
| AT (1) | ATE324883T1 (es) |
| AU (1) | AU2002331094B2 (es) |
| BR (1) | BR0212155A (es) |
| CA (1) | CA2456604C (es) |
| CO (1) | CO5560554A2 (es) |
| CY (1) | CY1106137T1 (es) |
| DE (1) | DE60211183T2 (es) |
| DK (1) | DK1425005T3 (es) |
| EC (1) | ECSP044986A (es) |
| ES (1) | ES2263813T3 (es) |
| HK (1) | HK1087336A1 (es) |
| HU (1) | HUP0401429A2 (es) |
| IL (1) | IL160375A0 (es) |
| MX (1) | MXPA04001933A (es) |
| MY (1) | MY137516A (es) |
| NO (1) | NO20040860L (es) |
| NZ (1) | NZ531342A (es) |
| PE (1) | PE20030323A1 (es) |
| PL (1) | PL367464A1 (es) |
| PT (1) | PT1425005E (es) |
| RU (1) | RU2329801C2 (es) |
| SI (1) | SI1425005T1 (es) |
| WO (1) | WO2003020261A1 (es) |
| ZA (1) | ZA200400877B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR030630A1 (es) * | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
| GB0201520D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Pharmaceutical uses |
| KR20040089654A (ko) * | 2002-03-07 | 2004-10-21 | 노파르티스 아게 | 약제학적 조성물 |
| NZ602496A (en) | 2008-08-19 | 2013-09-27 | Xenoport Inc | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US20140093563A1 (en) * | 2011-06-13 | 2014-04-03 | Ranbaxy Laboratories Limited | Febuxostat compositions |
| US10952968B2 (en) | 2012-05-14 | 2021-03-23 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
| EP2887935A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| ES2750323T3 (es) * | 2014-01-10 | 2020-03-25 | Johnson & Johnson Consumer Inc | Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| EP3162362A1 (de) * | 2015-10-30 | 2017-05-03 | Dr. Falk Pharma Gmbh | Optimierte mesalazinhaltige hochdosistablette |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163111C (en) * | 1993-06-08 | 2010-10-26 | Peter Heinrich Stahl | Process for the preparation of an oral solid dosage form containing diclofenac |
| CN1140267C (zh) * | 1996-05-17 | 2004-03-03 | 麦克公司 | 治疗环加氧酶-2介导的疾病的每天一次的组合物 |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| AR030630A1 (es) * | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
-
2002
- 2002-08-29 US US10/231,438 patent/US20030114527A1/en not_active Abandoned
- 2002-08-29 AR ARP020103257A patent/AR036312A1/es unknown
- 2002-08-29 PE PE2002000832A patent/PE20030323A1/es not_active Application Discontinuation
- 2002-08-30 HU HU0401429A patent/HUP0401429A2/hu unknown
- 2002-08-30 PL PL02367464A patent/PL367464A1/xx not_active Application Discontinuation
- 2002-08-30 CN CNB02816895XA patent/CN100406008C/zh not_active Expired - Fee Related
- 2002-08-30 PT PT02767455T patent/PT1425005E/pt unknown
- 2002-08-30 NZ NZ531342A patent/NZ531342A/en not_active IP Right Cessation
- 2002-08-30 DK DK02767455T patent/DK1425005T3/da active
- 2002-08-30 MY MYPI20023252A patent/MY137516A/en unknown
- 2002-08-30 CA CA2456604A patent/CA2456604C/en not_active Expired - Fee Related
- 2002-08-30 WO PCT/EP2002/009701 patent/WO2003020261A1/en active IP Right Grant
- 2002-08-30 MX MXPA04001933A patent/MXPA04001933A/es active IP Right Grant
- 2002-08-30 BR BR0212155-7A patent/BR0212155A/pt not_active IP Right Cessation
- 2002-08-30 ES ES02767455T patent/ES2263813T3/es not_active Expired - Lifetime
- 2002-08-30 IL IL16037502A patent/IL160375A0/xx unknown
- 2002-08-30 RU RU2004109920/15A patent/RU2329801C2/ru not_active IP Right Cessation
- 2002-08-30 AT AT02767455T patent/ATE324883T1/de active
- 2002-08-30 SI SI200230367T patent/SI1425005T1/sl unknown
- 2002-08-30 EP EP02767455A patent/EP1425005B1/en not_active Expired - Lifetime
- 2002-08-30 AU AU2002331094A patent/AU2002331094B2/en not_active Ceased
- 2002-08-30 KR KR1020047002925A patent/KR100895551B1/ko not_active IP Right Cessation
- 2002-08-30 JP JP2003524569A patent/JP4636796B2/ja not_active Expired - Fee Related
- 2002-08-30 DE DE60211183T patent/DE60211183T2/de not_active Expired - Lifetime
-
2004
- 2004-02-03 ZA ZA200400877A patent/ZA200400877B/en unknown
- 2004-02-25 EC EC2004004986A patent/ECSP044986A/es unknown
- 2004-02-25 CO CO04016658A patent/CO5560554A2/es not_active Application Discontinuation
- 2004-02-26 NO NO20040860A patent/NO20040860L/no not_active Application Discontinuation
-
2006
- 2006-07-10 HK HK06107694.8A patent/HK1087336A1/xx not_active IP Right Cessation
- 2006-08-03 CY CY20061101093T patent/CY1106137T1/el unknown
-
2007
- 2007-05-17 US US11/804,284 patent/US20070231382A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030323A1 (es) | Composicion farmaceutica | |
| BRPI0618455A2 (pt) | composição de geléia | |
| BRPI0403935B8 (pt) | formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
| AR087210A2 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
| SI1898876T1 (sl) | MUKOADHEZIVNE FARMACEVTSKE OBLIKE, KI VSEBUJEJO KSILOGlUKAN IN SO UPORABNE V MEDICINSKIH SREDSTVIH IN APLIKACIJSKIH OBLIKAH | |
| ES2159591T3 (es) | Composicion de liberacion controlada. | |
| UY28236A1 (es) | Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos. | |
| AR061771A1 (es) | Sistema de administracion terapeutica | |
| NZ594071A (en) | Controlled release formulations comprising morphine sulphate for continuous treatment of pain | |
| BR0317104A (pt) | Composições farmacêuticas dispersáveis | |
| ECSP045102A (es) | Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo | |
| NZ609719A (en) | Pharmaceutical composition | |
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| CU23367A3 (es) | Formulación de moxifloxacino con sal común | |
| BR0306501A (pt) | Método para uso e produção de um tampão com medicamento | |
| GB2456475A (en) | Composition for the treatment of skin conditions | |
| AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
| GT200200115AA (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion . | |
| RS51154B (sr) | Farmaceutske kompozicije koje sadrže niske koncentracije peroksida za lečenje i sprečavanje vaginalnih infekcija | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
| BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
| ECSP11010941A (es) | Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual | |
| CN103181911B (zh) | 一种阴道泡腾片 | |
| BRPI0418963A (pt) | composição para redução de gordura localizada, uso de compostos tensoativos farmceuticamente aceitáveis e métodos para redução de gordura localizada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |